TABLE 3.
Concurrent medications, nutritional therapy and polyunsaturated fatty acid supplementation in 39 dogs comprising the intention‐to‐treat population
| Enalapril group | Telmisartan group | ||
|---|---|---|---|
| Total number | 19 | 20 | |
| Clinical renal diet | Yes | 17 (89%) | 15 (75%) |
| No | 2 (11%) | 5 (25%) | |
| Polyunsaturated fatty acid supplementation | Yes | 18 (95%) | 16 (80%) |
| No | 1 (5%) | 4 (20%) | |
| Concurrent oral medications | Levothyroxine | 2 (11%) | 2 (10%) |
| Trilostane | 0 | 1 (5%) | |
| Phenylpropanolamine | 1 (5%) | 2 (10%) | |
| Ursodeoxycholic acid | 2 (11%) | 1 (5%) | |
| S‐Adenosylmethionine + silybin | 0 | 2 (10%) | |
| Pimobendan | 1 (5%) | 1 (5%) | |
| Amlodipine a | 6 (32%) | 4 (20%) | |
| Gabapentin | 0 | 1 (5%) | |
| Tramadol | 3 (16%) | 0 | |
| Trazodone | 1 (5%) | 1 (5%) | |
| Amantadine | 0 | 1 (5%) | |
| Carprofen | 0 | 1 (5%) | |
| Clopidogrel | 0 | 1 (5%) | |
| Maropitant | 0 | 1 (5%) | |
| Famotidine | 1 (5%) | 0 | |
| Metoclopramide | 0 | 1 (5%) | |
| Metronidazole | 0 | 1 (5%) | |
| Theophylline | 0 | 1 (5%) | |
| Hydrocodone | 0 | 1 (5%) | |
| Diphenhydramine | 0 | 1 (5%) | |
| Ophthalmic ointments | Cyclosporine | 1 (5%) | 0 |
| Neomycin/Polymixin B/Gramicidin | 1 (5%) | 0 | |
| Neomycin/Polymixin B | 1 (5%) | 0 | |
| Injectable | Canine Atopic Dermatitis Immune IL‐31 monthly | 0 | 1 (5%) |
Note: Concurrent medications are reported if administered at least once at any point during the study. Data are presented as number of dogs (%).
a
One dog in each group was receiving amlodipine prior to study enrollment. In the remainder, amlodipine was added as part of study protocol.